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p53 activity is essential for normal development in Xenopus
John B. Wallingford, Daniel W. Seufert, Valerie C. Virta and Peter D. Vize
Background: The tumor suppressor p53 plays a key role in regulating the cell
cycle and apoptosis in differentiated cells. Mutant mice lacking functional p53
develop normally but die from multiple neoplasms shortly after birth. There
have been hints that p53 is involved in morphogenesis, but given the relatively
normal development of p53 null mice, the significance of these data has been
difficult to evaluate. To examine the role of p53 in vertebrate development, we
have determined the results of blocking its activity in embryos of the frog
Xenopus laevis. 
Results: Two different methods have been used to block p53 protein activity in
developing Xenopus embryos — ectopic expression of dominant-negative forms
of human p53 and ectopic expression of the p53 negative regulator, Xenopus
dm-2. In both instances, inhibition of p53 activity blocked the ability of Xenopus
early blastomeres to undergo differentiation and resulted in the formation of
large cellular masses reminiscent of tumors. The ability of mutant p53 to induce
such developmental tumors was suppressed by co-injection with wild-type
human or wild-type Xenopus p53. Cells expressing mutant p53 activated
zygotic gene expression and underwent the mid-blastula transition normally.
Such cells continued to divide at approximately normal rates but did not form
normal embryonic tissues and never underwent terminal differentiation,
remaining as large, yolk-filled cell masses that were often associated with the
neural tube or epidermis.
Conclusions: In Xenopus, the maternal stockpile of p53 mRNA and protein
seems to be essential for normal development. Inhibiting p53 function results in
an early block to differentiation. Although it is possible that mutant human p53
proteins have a dominant gain-of-function or neomorphic activity in Xenopus,
and that this is responsible for the development of tumors, most of the evidence
indicates that this is not the case. Whatever the basis of the block to
differentiation, these results indicate that Xenopus embryos are a sensitive
system in which to explore the role of p53 in normal development and in
developmental tumors.
Background
Many mutant p53 alleles are oncogenic, and p53 was in fact
first thought to be an oncogene as the first clones isolated
corresponded to mutant forms expressed in immortalized
cell lines. Expression of mutant p53 immortalizes primary
fibroblasts, and in combination with mutant Ras transforms
such cells [1–3]. Normal p53, however, functions as a
tumor suppressor and its overexpression can inhibit the
growth of various tumor cell lines and can block the trans-
forming activity of a variety of oncogenes [4,5]. The p53
protein possesses several different biochemical activities,
including transcriptional activation and repression, binding
to single-stranded DNA, and interaction with several het-
erologous proteins, (reviewed in [5–7]). These activities
regulate a diverse array of biological processes, for example
cell cycle transitions, apoptosis, and response to DNA
damage [5–7]. Elimination of p53 activity is thought to
contribute to the initiation or progression of tumorigenesis
by loss of cell cycle control, genomic instability, and the
acquisition of novel properties, such as resistance to
hypoxia [5–8]. Given this involvement in numerous funda-
mental processes, it is quite surprising that p53 null mice
develop to term in the majority of cases [9–11]. However,
p53 is expressed during early murine development in a
pattern consistent with a role in differentiation [12–15],
and the precise regulation of expression appears to be
essential for normal development [16,17].
Observations from transgenic mice and tissue culture
experiments raise the possibility that p53 may be required
for normal differentiation in some cell types. Foremost
among these observations is the high incidence of neural
tube and craniofacial abnormalities observed in p53 null
mice in some genetic backgrounds [10,11]. Furthermore,
transgenic mice are under-represented in the offspring of
transgenics expressing mutant p53 [18]. Other in vitro
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observations consistent with a developmental role include
a possible requirement for p53 in hematopoiesis [19,20],
muscle differentiation [20], and neural differentiation
[21,22]. The possibility of a role for wild-type p53 in early
development has been the subject of recent reviews by
Hall and Lane [23] and Rotter et al. [24]. These data
suggest that either p53 has an essential role in some aspect
of differentiation, or that the lack of p53 activity results in
the rapid accumulation of genetic lesions, which in turn
inhibit normal development. In order to investigate the
function of p53 during early embryogenesis, the activity of
the p53 protein was inhibited in a simple model system
useful for investigating vertebrate development, the
Xenopus embryo. The very rapid development of this
animal allows the requirement for this protein during
embryogenesis to be analyzed with little or no chance of
genetic damage playing a role.
Xenopus p53 is biochemically similar to human p53 [25],
and Xenopus embryos contain a ubiquitous maternal stock-
pile of p53 mRNA and protein [26,27]. Elimination of
protein function in Xenopus has been most effectively
achieved by overexpression of dominant-negative mutants
[28–31], and many mutant forms of p53 have been shown
to act in a dominant-negative manner, (for example
[32,33]). To examine the role of p53 in early Xenopus
development, synthetic mRNA encoding various domi-
nant-negative forms of human p53 was microinjected into
early Xenopus embryos. As some mutant p53 proteins have
been reported to have subtle gain-of-function activities in
addition to the ability to block the function of wild-type
p53 in a dominant-negative manner [34], the activity of
p53 was also inhibited by overexpressing Xdm-2, the
Xenopus ortholog of the murine double minute-2 (mdm-2)
gene, which encodes a negative regulator of p53 activity
[35–38]. The result of inhibiting p53 activity by either of
these approaches was the same: differentiation was
blocked. Cells expressing either mutant p53 or Xdm-2 con-
tinued to divide at approximately normal rates but failed
to differentiate and remained as cell masses, or tumors.
These data indicate that p53 activity is essential for differ-
entiation in Xenopus.
Results and discussion
Dominant-negative p53 induces the formation of
developmental tumors
In order to inactivate the maternal stockpile of Xenopus
p53, synthetic mRNA encoding a dominant-negative form
of human p53, p53Thr280 [39], was microinjected into a
single blastomere in the presumptive mesoderm of 32-cell
stage embryos along with mRNA encoding nuclear β-galac-
tosidase as a lineage tracer [40]. Injected embryos were
then raised to tadpole stages, fixed, and stained for β-galac-
tosidase activity (Figure 1a). Injection of β-galactosidase
mRNA alone had no effect on development (Table 1), and
in such control experiments, β-galactosidase-positive cells
were found evenly incorporated into axial structures
(Figure 1a). However, in embryos co-injected with
p53Thr280 mRNA, the β-galactosidase-positive cells derived
from the injected blastomere were found to be clustered
into large cell masses, with no organization into axial struc-
tures (Figure 1a and Table 1). Cell masses were most
obvious at the late tailbud stage. These cell masses often
persisted through to feeding tadpole stage, although
diminished in size, without becoming incorporated into
tissues. As injected mRNAs are only stable in Xenopus
embryos until neurula stages [41], the cell masses persist
long after the mutant p53 mRNA which led to their forma-
tion has been degraded. It is possible that the undifferenti-
ated cell masses miss the temporal window when cells are
competent to differentiate or when the embryonic signals
triggering differentiation are present.
Histological analysis revealed that the cell masses formed
by cells expressing p53Thr280 resembled tumors in a
number of ways. The cell masses were nucleated and the
cells within them were of approximately normal size and
retained large numbers of yolk platelets, reminiscent of
undifferentiated cells (Figure 1b,c). Furthermore, abnor-
mal nuclear morphologies were observed (Figure 1d), and
the cell masses were sometimes surrounded by an epithe-
lial capsule and were often adjacent to large deposits of
extracellular matrix. Many tumors had associated
melanocytes, either superficial or integrated (Figure 1b,c).
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Table 1
Frequency of developmental tumor formation in response to
ectopic expression of tumor suppressors or proto-oncogenes. 
Injected mRNA Tumor N No. 
frequency (%) experiments
0.5 ng β-gal 0 66 8
0.5 ng p53Thr280 67 120 2
0.5 ng p53Trp248 71 34 2
0.5 ng Hp53 0 94 2
0.5 ng Xp53 0 38 1
1 ng xWT1 0 106 11
1.5 ng p53His175 54 114 2
1.5 ng Xdm-2 30 249 4
Wild-type tumor suppressors p53 (both human and Xenopus) and
WT1 (Xenopus) do not induce tumor formation. Mutant p53 and wild-
type Xdm-2 cause developmental tumors in a large percentage of
injected embryos. The distribution of β-galactosidase-positive cells
(see Figure 2) was used to score the frequency of tumor formation,
and tumor phenotypes were confirmed by histology. p53His175 was not
cloned into the expression vector 64TS and mRNA was generated
from pBS (see Materials and methods); such mRNA will have a
significantly lower translational efficiency [40], which may explain the
reduced frequency of tumor formation for this mutant.  β-gal, β-
galactosidase; Xp53, Xenopus wild-type p53; Hp53, human wild-type
p53; xWT1, Xenopus wild-type WT1 [71].
As these tumors are derived from embryonic cells that have
failed to differentiate, rather than from cells that have
undergone dedifferentiation, they can be classified as blas-
tomas, or undifferentiated embryonic-derived tumors.
Blocking p53 activity did not overtly interfere with or
promote cell proliferation. As Xenopus early development
proceeds without growth, cell division results in the for-
mation of smaller and smaller cells with each cell cycle.
When a single blastomere was injected with mutant p53, it
gave rise to tumors containing hundreds of cells of approx-
imately normal size (see Figure 1), indicating that these
cells have undergone an approximately normal number of
divisions. Although some tumor nuclei are pycnotic (not
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Figure 1
Expression of dominant-negative p53 results
in the formation of developmental tumors. 
(a) Experimental protocol. Xenopus embryos
were fertilized in vitro. At the 32-cell stage, a
single blastomere was either co-injected with
β-galactosidase and mutant p53 mRNA, or
injected with β-galactosidase alone. Embryos
were injected into one side only, allowing the
uninjected side to act as an internal control for
normal development. Injected embryos were
reared to the swimming tadpole stage, fixed,
and stained to detect the presence of 
β-galactosidase activity. Cells expressing 
β-galactosidase (light blue) alone
incorporated into axial structures such as
somites (upper embryo). Cells expressing
p53Thr280 plus β-galactosidase did not
contribute to normal embryonic structures and
were clumped together into large cell masses,
or tumors (lower embryo). (b) Transverse
section through an embryo injected into the
presumptive somite with β-galactosidase and
p53thr280 mRNAs. Morphology on the
uninjected control (left) side is normal and
illustrates normal anatomy at this stage of
Xenopus development; the epithelium of the
neural tube is intact and the somite extends
dorsally, lateral to the neural tube. A tumor is
obvious on the injected (right) side. (c) Higher
magnification image of the injected (right) side
of the transverse section shown in (b). The
tumor is continuous with the spinal cord and
the neural epithelium is disrupted. The tumor
is partially covered by pigmented melanocytes
[red arrows; also see panel (e)], as is the
spinal cord. The cells within the tumor contain
numerous yolk platelets (black arrows),
reminiscent of undifferentiated cells. Note that
the somite ventral to the tumor is reduced in
size compared to the somite on the uninjected
(control) side. Section shown in (b) and (c)
was stained with hematoxylin and eosin, but
cells retain a low level of the β-galactosidase
stain (light blue/green). (d) Transverse section
through the same specimen as in (b), stained
with Sytox green to visualize nuclei. The tumor
is nucleated and contains cells of
approximately normal size. An abnormally
shaped nucleus is indicated with a white
arrow. The tumor is surrounded by an
epithelial capsule (pink arrows). 
(e) Transverse section through the same
specimen as shown in (d); specimen has not
been stained so that β-galactosidase positive
cells are easily visible. All of the
undifferentiated cells of the tumor are 
β-galactosidase positive. High resolution
images of the tumors illustrated in this paper
can be viewed on the World Wide Web at
URL http://vize222.zo.utexas.edu/p53.html
(b) (c)
(a)
(e)(d)
β-galactosidase positive tumor
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shown), extensive apoptosis was not triggered by blocking
p53 activity, as evidenced by the low frequency of such
pycnotic nuclei and the continued presence of β-galactosi-
dase-positive tumor cells. Although low levels of p53
block apoptosis in some systems [42,43], pycnotic nuclei
are not commonly observed in normal Xenopus embryos at
this stage of development; the mutant p53 is thus unlikely
to be leading to tumor formation by blocking the low level
of normal apoptosis. These observations indicate that the
formation of tumors is not likely to be the result of prolif-
erative or apoptotic defects, but rather is the result of the
failure of cells to be incorporated into normal tissues and
to undergo differentiation.
When embryos were injected into the presumptive
somitic mesoderm, cells expressing a dominant-negative
p53 were often displaced dorsally and lay adjacent to the
neural tube just below the epidermis (Figure 1b,c). In
many instances, such tumors were integrated into the
adjacent differentiated epidermis or neural tube.
However, these cells did not take on the morphology of
neural or epidermal epithelial cells (Figure 1b,c). In many
cases where tumors were found lateral to the neural tube,
the somite on the injected side of the embryo was
restricted ventrally and greatly reduced in size (Figure
1b). This reduction of the somite may be a result of tissue
distortion caused by the presence of the tumor, but is
more likely due to the failure of p53Thr280-expressing cells
to differentiate and consequent failure of these cells to
contribute to the somitic tissue. Tumors were also, though
more rarely, found associated with mesodermal tissues
such as somite and pronephros (Figure 2).
The phenotype elicited by mutant p53 was not due to
non-specific effects caused by mRNA toxicity, as overex-
pression of wild-type human or Xenopus p53 never induced
tumor formation or inhibited normal differentiation (Table
1). Although it has been reported that overexpression of
wild-type Xenopus p53 results in cell cycle arrest [26], the
doses required to elicit such effects were extremely high,
the lowest dose being more than double the highest dose
injected here. In this study, injections of up to 1 ng of
Xenopus or human wild-type p53 never elicited cell cycle
arrest or tumor formation. Likewise, injection of β-galac-
tosidase mRNA alone, even at very high doses, had no
effect on development (Table 1). Furthermore, no tumors
have been reported in Xenopus embryos in previous studies
in which other gene products were ectopically expressed,
including other tumor suppressor genes such as APC [44]
and WT1 (Table 1), proto-oncogenes such as jun [31] and
ras [45], viral oncogenes such as polyoma middle T [46]
and v-ras [45], or cyclins such as cyclin B2 [47].
Dominant-negative p53 inhibits differentiation
Histological analysis revealed that cell masses expressing
dominant-negative p53 appeared to be undifferentiated
(Figure 1), and p53 has been suggested to be involved in
the differentiation of a number of cell types in vitro
[19–24]. We therefore used immunohistochemistry to
determine if elimination of p53 activity inhibited differen-
tiation in vivo in the developing Xenopus embryo.
The p53Thr280 mRNA was co-injected with β-galactosidase
mRNA into blastomeres fated to give rise to brain and
spinal cord (Table 2). At tadpole stages, cells that stained
positive for β-galactosidase (and therefore expressed
p53Thr280) and were associated with the neural tube were
analyzed for the expression of markers of neural differen-
tiation using wholemount immunohistochemistry. Such
tumors failed to stain with antibody XAN3/6F11 (Figure
3a), an early marker of neural cells [48]. Likewise, tumors
did not stain with antibody 2G9, which detects terminally
differentiated neurons (Figure 3b). p53Thr280 mRNA was
then co-injected with β-galactosidase mRNA into pre-
sumptive somitic blastomeres (Table 2). Tumors adjacent
to embryonic somites failed to stain with either of two
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Figure 2
Developmental tumor associated with multiple
tissues. (a) Transverse section and (b)
interpretative diagram illustrating a tumor that
is associated closely with the neural tube,
extends under the notochord and is
associated with the pronephros on the
opposite side of the embryo. The right side
was injected with mutant p53 mRNA. The
presence of tumor cells on both sides of the
midline is probably a consequence of the
movement of loosely adherent cells driven by
normal morphogenetic movements, rather
than of the undifferentiated cells possessing
any invasive properties.
pronephric
tubules
somite
neural
tube
notochord
somite
endoderm
pronephric
tubules
(a) (b)
antibodies that detect differentiated muscle, 12/101
(Figure 3c,d) [49] or 5A3 (not shown).
Some evidence has suggested that p53 may be involved in
the differentiation of the kidney [50, 51]. p53Thr280 mRNA
was therefore injected into blastomeres that give rise to
the kidney, and development of the kidney was assayed
with the pronephric tubule-specific antibody 3G8 [52].
p53Thr280 expression completely inhibited the differentia-
tion of pronephric tubules (Figure 3e,f).
In summary, targeted delivery of mutant p53 induced
tumor formation and inhibited differentiation in blas-
tomeres fated to give rise to epidermis (Table 2), neurec-
toderm and mesoderm (Figure 3 and Table 2), indicating
that p53 activity is required for differentiation in most, if
not all, Xenopus cell types.
Wild-type p53 suppresses the tumor-inducing activity of
mutant p53
Although mutant human p53 was overexpressed in these
experiments, Xenopus p53 is similar in structure and func-
tion to human p53 and can form functional heterotetramers
with human p53 [25,53]. If the mutant p53 blocks differen-
tiation by oligomerizing with and inhibiting the activity of
the endogenous Xenopus p53 protein, the effect should be
abrogated by co-injection with excess wild-type p53.
Indeed, when an excess of either human or Xenopus wild-
type p53 was coinjected with p53Thr280, the frequency of
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Figure 3
Mutant p53 blocks differentiation. (a) Dorsal
view of an embryo injected with p53Tthr280
mRNA plus β-galactosidase mRNA into
blastomere B1 of a 32-cell embryo, reared to
tailbud stage, and stained with the anti-neural
antibody XAN3/6F11 (dark blue/purple [48]).
Anterior is to the left. Note that the β-
galactosidase-positive tumor (light blue) does
not stain with the neural marker, and that the
large tumor distorts the brain into which it is
embedded. (b) Transverse section through a
sample similar to that shown in (a). Neural
staining (dark purple) with antibody 2G9
(Xenopus Molecular Marker Resource, URL
http://vize222.zo.utexas.edu) and β-
galactosidase (light blue). β-galactosidase-
positive cells do not stain with the neural
marker, and vice versa. (c) Control side of a
tailbud stage embryo stained (dark blue/purple)
with the somite differentiation marker
12/101[49]. Note that the differentiated
somites extend anteriorly to the head of the
embryo. (d) The opposite side of the embryo
shown in (c), illustrating a tumor derived from
blastomere C2 injected with p53thr280 mRNA
plus β-galactosidase mRNA. Note that the
region in which anterior somites should have
formed does not stain with 12/101, but is β-
galactosidase positive (light blue). (e) The
control side of a tailbud stage embryo stained
with antibody 3G8 [50] to detect pronephric
tubules (dark purple substrate, arrow).(f) The
opposite side of the embryo shown in (e),
illustrating a tumor derived from the blastomere
C3 injected with p53thr280 mRNA plus β-
galactosidase mRNA. The region in which the
embryonic kidney, the pronephros, should have
formed does not stain with antibody 3G8. The
β-galactosidase-positive tumor (light blue) is
displaced dorsally from the region in which the
pronephros normally develops, but such
displacement is common for mutant p53-
induced tumors (see Figures 1 and 5).
(a) (b)
(d)
(e) (f)
(c)
Table 2
Mutant p53 can block the differentiation of multiple cell
lineages. 
Injected Prospective Frequency N
blastomere fate of tumor formation (%) 
B1 or B2 Brain and 69 43/62
Spinal cord
C2 or C3 Somite 81 18/22
A4 Epidermis 63 29/46
The blastomeres were injected with 500 pg of p53thr280 mRNA plus 
β-galactosidase, raised to tadpole stages, and scored for tumor
frequency. Mutant p53 blocks the differentiation of blastomeres fated to
form somite, kidney, brain, spinal chord and epidermis. Blastomere
numbering and prospective fates are according to Dale and Slack [72].
tumor formation was dramatically reduced (Figure 4).
Considering that p53 functions as a tetramer, most
oligomers formed from a 4:1 mixture of wild-type to
mutant p53 protein will contain at least one mutant
subunit. This fact, in addition to the enhanced stability of
mutant p53 proteins [54–56] may explain the inability of
wild-type p53 to completely rescue the tumor phenotype.
Due to dosage constraints, greater amounts of wild-type
mRNA could not be tested.
Different p53 mutants elicit a similar developmental
phenotype
It is possible that the tumor phenotype was the result of
an activity unique to p53Thr280. Therefore, the activity of
other p53 dominant-negative mutants was evaluated using
identical protocols. The original mutant tested, p53Thr280,
disrupts an essential base contact in the DNA-binding
domain [39,57]. Another mutant, p53Trp248, disrupts DNA
binding by eliminating essential minor groove contacts
[57]. Expression of p53Trp248 elicited a tumor phenotype
identical to that of p53Thr280 in terms of frequency (Table
1), size, gross morphology, and histology (Figure 5). A
third mutant, p53His175, which disrupts protein folding in
the DNA-binding domain [57], also elicited a similar
tumor phenotype (Figure 5 and Table 1).
Ectopic Xdm-2 induces developmental tumors
The observation that wild-type p53 protein can block the
activity of a mutant protein and that three different p53
mutants induce similar tumors argues that the mutant
human p53 proteins block differentiation by inhibiting the
activity of endogenous Xenopus p53. It is possible,
however, that these different proteins possess a common
gain-of-function (neomorphic) activity and act via other
proteins not normally associated with wild-type p53. We
therefore sought to repress p53 activity without introduc-
ing mutant human proteins.
The mdm-2 gene encodes an oncoprotein which binds to
and inhibits the activity of the p53 transcriptional activa-
tion domain [35,36] and targets p53 for ubiquitin-medi-
ated degradation [37,38]. In order to eliminate p53
activity, mRNA injection was used to overexpress the
Xenopus ortholog of mdm-2, Xdm-2 [35], in developing
embryos. The expression of Xdm-2 during normal Xenopus
development has not yet been described; however, the
developmental expression of this gene is not relevant to
the experiments described here, as microinjected Xdm-2
was used only to interfere with the maternal stockpile of
p53, not endogenous Xdm-2.
Overexpression of Xdm-2 mRNA elicited a tumor pheno-
type quite similar to that of mutant p53 (Figure 5),
although at a lower frequency (Table 1). These tumors
were again identified initially by the failure of β-galactosi-
dase-positive cells to incorporate normally into axial struc-
tures of the embryo (not shown). Tumors resulting from
Xdm-2 overexpression were in general smaller than those
elicited by mutant p53; however, histological analysis
revealed that Xdm-2-induced tumors were similar in mor-
phology to those resulting from mutant p53 expression
(Figure 5). Xdm-2-induced tumors tended to be located in
aberrantly dorsal positions, contained yolk-filled, nucle-
ated cells, and were sometimes integrated into the neural
tube or epidermis (Figure 5d).
It is possible that Xdm-2 induces tumors at a lower fre-
quency than mutant p53 because of differences in protein
stability, stoichiometry of inhibitory mechanisms, or
because Xdm-2 possesses only a subset of the activities of
mutant p53. Xdm-2 may induce tumors by blocking
endogenous p53 activity, while mutant p53 proteins may
function both by blocking endogenous p53 and by gain-
of-function activities [34]. The early lethality observed in
mdm-2 null mice can be rescued by generating such mice
in a p53 null background, arguing that the only essential
function of mdm-2 during normal development is the
regulation of p53 activity [16,17]. Given this observation,
it would seem that the Xdm-2 induced developmental
tumors represent the minimal consequence of blocking
p53 activity in Xenopus. A quantitative biochemical
analysis of the effects of Xdm-2 and mutant p53 on the
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Figure 4
Wild-type p53 rescues the mutant p53 phenotype. (a) The
distribution of β-galactosidase-positive cells [as shown in (b) and (c)]
was used to score the frequency of tumor formation in this assay,
and tumor phenotypes were confirmed by histology. Four-fold
overexpression of either Xenopus or human wild-type p53 reduced
tumor frequency by more than half. (b) Embryo injected with 125 pg
of p53Thr280 mRNA plus β-galactosidase mRNA and stained for β-
galactosidase activity; cells expressing β-galactosidase (blue) clump
together into distinct cell masses or tumors (arrow). (c) Embryo
injected with125 pg p53Thr280 plus 500 pg of human wild-type p53
and β-galactosidase as a lineage tracer; cells expressing β-
galactosidase are distributed normally across the embryo and
incorporated into normal tissues.
(b) (c)
(a) Tumor 
frequency
N No. of
experiments
125 pg p53thr280 66% 249   8
125 pg p53thr280 30% 113   5
+ 500 pg Xenopus  p53
125 pg p53thr280 32% 128   4
+ 500 pg human p53
Injected mRNA(s)
transcriptional activity of endogenous p53 will be required
to explore this issue.
Mutant p53 does not interfere with the mid-blastula
transition
In Xenopus embryos, the first 12 cell cycles do not contain
G1 or G2 phases; the cell cycle acquires these phases only
after the mid-blastula transition (MBT), concomitant with
the onset of zygotic gene expression and the loss of cell
cycle synchrony [58,59]. One possible role for p53 in early
amphibian development could be to implement G1 and
G2 cell cycle control at the MBT. In order to examine this
possibility, the MBT was analyzed in embryos injected
with p53Thr280 into all cells at the four-cell stage. Zygotic
transcription was activated normally (Figure 6) and the
cell cycle became asynchronous at the MBT in embryos
expressing p53Thr280 in all cells (not shown), indicating
that the MBT occurred normally. Not only does general
transcriptional activation commence normally, as indicated
by the activation of a housekeeping gene, EF-1α [60], but
mesodermal gene expression also commences normally, as
evidenced by the activation of Brachyury [61] and goosecoid
[62] expression. This indicates that the mutant p53 is not
blocking mesoderm induction. Rather, mutant p53 seems
to be acting by blocking cells’ ability to act on these
signals and differentiate into mesoderm.
The p53 protein contains a negative regulatory domain in
its carboxyl terminus; when this domain is unphosphory-
lated, the transcriptional activation activity of p53 remains
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Figure 5
(a) (b)
(c) (d)
(a′) p53thr280
(b′) p53his175
(c′) p53trp248
(d′) Xdm-2
ecm notochord
somite
neural tubetumor
Morphology of developmental tumors resulting from expression of
various p53 mutants or Xdm-2. All panels illustrate transverse sections
stained with hematoxylin and eosin. The left side of the embryo was
injected in all cases. Schematic representation of each panel illustrating
the borders of each tumor is shown in a‘–d‘. (a) p53Thr280-induced
tumor. The tumor bulges out from the lateral surface of the spinal cord.
The somite on the injected side is restricted ventrally (compare with
uninjected control side). (b) p53His175-induced tumor. The tumor is
continuous with the dorsal spinal cord and the overlying epidermis, and
occupies much of a space filled with extracellular matrix lateral to the
spinal cord where the somite is normally present. (c) p53Trp248-induced
tumor. The tumor is integrated into the dorsal neural tube and extends
ventrolaterally where somite is normally present. (d) Xdm-2-induced
tumor. The tumor is integrated into the epidermis dorsal to the
hindbrain. Tumors in all cases contain a high density of yolk platelets
and appear to be undifferentiated. Scale bar = 100µm. Scale is similar
in (a)–(c). ecm, extracellular matrix. The hematoxylin and eosin staining
protocol removes the stain from the lineage tracer in most instances.
latent [63]. The observation that inhibition of p53 activity
does not affect cleavage (not shown) or the MBT (Figure
6) suggests that the maternal stockpile of p53 protein in
the Xenopus embryo [26,27] may remain inactive and play
no part until after the MBT, when embryonic cells begin
to differentiate. This hypothesis is consistent with the
finding that functionally inactive p53 protein in teratocar-
cinoma cells is activated upon differentiation [64,65].
A role for p53 in development
Taken together, these results suggest a crucial role for p53
in early Xenopus development. Although dominant-negative
p53 mutants may have gain-of-function activities, the fact
that Xdm-2 elicits a strikingly similar phenotype argues that
the mutant proteins are likely to be acting by interfering
with endogenous p53. If a gain-of-function activity is
responsible, this activity must be shared by three different
mutants and a distinct tumor phenotype must be elicited by
ectopic Xdm-2. Although this would be an extraordinary
coincidence, we are performing experiments to eliminate
this possibility by interfering with p53 activity by other
means and by examining the effect of mutant p53 and wild-
type Xdm-2 on the biochemical activity of embryonic p53.
The most likely explanation for the data presented here is
that p53 activity is essential for normal development in
Xenopus, and that interfering with p53 function results in
blocking the ability of embryonic cells to differentiate.
How can p53 be essential to frog development but largely
dispensable during murine development? One possibility
is that p53 is required for a developmental process that is
not utilized during murine development. The mostly
likely candidate process would be the mid-blastula transi-
tion, which is critical to frog development but has no true
equivalent in mice. The data shown in Figure 6 indicate,
however, that the MBT occurs normally and so cannot
explain the incongruence between mouse and frog obser-
vations. The Xenopus embryonic cell cycle undergoes a
second transition period a few cycles after the MBT. This
second transition is known as the early gastrula transition
(EGT) and is characterized by a significant lengthening of
the gap phases of the cell cycle [63]. This lengthening
may reflect the acquisition of additional checkpoints or
other cell cycle properties, and these additional properties
may be essential for differentiation. The timing of the
EGT is consistent with the defects observed in response
to blocking p53 activity, as the first stages at which defects
have been identified are early neurulae, shortly after the
end of gastrulation.
Xenopus embryos contain a large maternal stockpile of p53
mRNA and protein [27], and murine teratocarcinoma cells
are known to contain a stockpile of inactive p53 protein
that is activated in response to differentiation signals [65].
However, mammalian embryos express only low levels of
p53 [12] and maternal stocks of p53 have not been
described. Furthermore, a maternal stockpile of p53
protein in p53 null mice cannot explain the lack of an
early effect on mouse development, as p53 null mice can
be crossed and produce viable offspring [10]. It is possible
that the Xenopus stockpile is utilized for some as yet
uncharacterized, but essential, aspect of differentiation. A
temporal analysis of the DNA-binding and transcriptional
activating activity of this stockpile may help to define the
process(es) for which it is required.
Another possibility is that mice have genetic redundancies
not present in frogs, making Xenopus more sensitive to p53
inhibition. For example, in mammals, mutation of MyoD
or Myf-5 does not disrupt myogenesis, but combination of
the two mutants does [66]. The detailed analysis of MyoD
mutants alone would not have predicted a role for this
important gene in muscle development. Other useful
examples are the activins, which seem to be essential for
mesoderm induction in Xenopus [28] but not for mesoderm
formation in mice [67,68]. Once again, excluding a role for
this gene in development  solely on the basis of the mouse
mutant phenotype would have been premature. Lower
vertebrates may have less complex redundancies protect-
ing proliferation and differentiation, making them more
dependent on p53 function. It is interesting to note that
developmental defects in p53 null mice occur at different
frequencies in different genetic backgrounds [10,11],
implying that at least some such functional redundancies
exist, and that without these redundancies p53 function is
necessary for normal development.
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Figure 6
Dominant-negative p53 does not inhibit the mid-blastula transition
(MBT). Four-cell embryos were injected with p53Thr280 mRNA into all
four cells (+); control embryos were uninjected (–) . At stage 6,
embryos injected with p53Thr280 mRNA (+) and uninjected embryos (–)
both express low levels of EF-1α, but do not express goosecoid or
Brachyury. Following the MBT, at stage 10.5 and stage 13, EF-1α
expression is upregulated and zygotic expression of goosecoid and
Brachyury commences equally in injected (+) and uninjected (–)
embryos. –RT, no reverse transcriptase control.
+       – +       – +      –M
B
T
6 10.5 13
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This hypothesis is further supported by evidence from
cultured mammalian cells. For example, elimination of
p53 activity inhibits differentiation of at least two differ-
ent hematopoietic lineages [19,20]. Furthermore, domi-
nant-negative p53 inhibits the differentiation of primary
cultures of mammalian neurons [21]. Expression of domi-
nant-negative p53 also inhibits the differentiation of cul-
tured mammalian myoblasts [20]. These observations are
consistent with our data indicating that inhibition of p53
activity blocks the differentiation of neural and muscle
tissue (Figure 3). The elimination of p53 activity in
various cell lines inhibited differentiation without altering
the cell cycle [20], a result consistent with our in vivo
observations in Xenopus embryos in which differentiation
was also blocked without overtly affecting proliferation.
Together these data indicate a new biological role for p53
as a regulator of cell differentiation in vertebrates.
The commonly used p53Val135 transgenic mice express a
rather weak temperature-sensitive mutation under the
control of the p53 promoter [18]. As mutant proteins must
be present in excess to interfere effectively with wild-type
protein [6], these mice may not really address the question
of a role for p53 in development. High-level expression of
a potent dominant-negative p53 mutant protein during
early murine development may well have more penetrant
effects than targeted p53 disruption, especially if mutant
proteins possess a weak gain-of-function activity in addi-
tion to their dominant-negative activity. We are examining
the activity of p53Thr280 on very early murine development
to explore this issue. If the existence of genetic redundan-
cies is the reason for the lack of a penetrant phenotype in
p53 null mice, the lack of such redundancies in Xenopus
may provide a system in which the redundant genes can
be identified. Microinjection of mutant p53 mRNA plus
pools of mRNAs from mammalian cell lines into Xenopus
embryos and screening for the ability of such pools to sup-
press tumor formation may allow the identification of the
redundant genes. If such genes exist, their identification
will be relevant to the study of human tumorigenesis.
Given that investigations into the developmental role of
p53 in two organisms — mice and frogs — have produced
different  conclusions, it is of interest to know which result
is the more typical of vertebrates. Even if p53 has a role in
other organisms equivalent to its role in Xenopus, blocking
p53 activity in a fraction of their cells may have less spec-
tacular consequences. For example, if the Xenopus tumors
are due simply  to cells dividing in situ and never integrat-
ing into embryonic tissues, such tumors may only be gen-
erated in an organism that develops with little cell mixing.
In more mosaic mouse or zebrafish embryos, cells express-
ing mutant p53 may indeed fail to differentiate, but due to
extensive cell mixing undifferentiated cells may end up
being distributed throughout the embryo or in extra-
embryonic tissues and, therefore, fail to form the large
subepidermal masses observed in Xenopus. The fact that
different results have been obtained indicates that this is
an issue worthy of further exploration.
Conclusions
Blocking p53 activity by ectopic expression of mutant p53
protein or by wild-type Xdm-2 inhibits differentiation
without overtly interfering with cell division or early
zygotic gene expression. This block to differentiation can
be suppressed by wild-type p53. These results indicate
that p53 activity is essential for normal development in
Xenopus, providing an important counterpart to the obser-
vation that loss of p53 activity is so intimately associated
with the reverse process — loss of differentiation.
These results show the usefulness of this embryonic
system for evaluating the biological activity of mutant p53
genes. Despite the wealth of knowledge of p53’s bio-
chemical activities and how this protein is modified in
human cancers, it is still not clear how mutant p53 pro-
teins contribute to the initiation or progression of cancer.
The system described here will provide a sensitive, simple
and rapid assay for evaluating the activity of p53 mutants
in both embryogenesis and tumorigenesis, without the
inherent problems of genomic instability observed in
transgenic animals and cultured cells. By studying a
single, reproducible and penetrant activity on early devel-
opment rather than the complexities engendered by the
unique nature of each transformation event in mammalian
tumors, we may be able to progress towards understanding
the key role of this protein during both differentiation and
dedifferentiation.
Materials and methods
Constructs and injections
Mutant and wild-type p53 cDNAs, and Xdm-2 cDNA, were subcloned
into the Xenopus expression vector pSP64TS, which provides
Xenopus globin 3′ and 5′ untranslated regions that significantly
improve translation efficiency, with the exception of p53His175, which
was used in pBS-SK (Stratagene). Capped mRNA was transcribed in
vitro [69], and embryo handling, microinjections (2–5 nl) and β-galac-
tosidase assays were performed as previously described [40] with the
exception that fixation prior to β-galactosidase development was per-
formed using MEMFA (0.1 M MOPS, pH 7.4, 2 mM EGTA, 1 mM
MgSO4, 3.7% formaldehyde) for 25 min only. Embryos were staged
according to Nieuwkoop and Faber [70].
Immunohistochemistry and histology
Embryos were fixed in MEMFA, stained for β-galactosidase activity [40]
and processed in one of two ways. Some specimens were stained for
antibodies 2G9 or XAN3/6F11 (neural), 12/101 or 5A3 (muscle), 3G8
(pronephros), or EPA (epidermis) using whole-mount immunocyto-
chemistry, embedded in JB-4 (Polysciences), sectioned at 5 µm, and
counterstained with Sytox green (Molecular Probes) or hematoxylin
and eosin (Sigma). Other specimens were embedded in Paraplast,
sectioned at 10 µm, and stained with antibodies using serial-section
immunochemistry. This procedure yielded better penetration of the anti-
body into the specimens.
RT-PCR
Embryos were injected with 0.5 ng p53thr280 into the marginal zone of
all four cells at the four cell-stage; control embryos were uninjected.
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Total RNA was extracted from five embryo equivalents at stages 6, 10.5,
and 13 and reverse transcribed. The polymerase chain reaction (PCR)
was performed using one tenth of each reverse transcription reaction,
Taq polymerase, 1 µCi of 32P-dATP, and primer sets listed below; cycle
temperatures were 92°, 55°, and 72°; EF-1α for16 cycles; goosecoid
and Brachyury for 19 cycles. Primer sets were as follows: EF-1α:
CAGATTGGTGCTGGATATGC and ACTGCCTTGATGACTCCTAG;
goosecoid: ACAACTGGAAGCACTGGA and TCTTATTCCAGAG-
GAACC; Brachyury: GGATCGTTATCACCTCTG and GTGTAGTCTG-
TAGCAGCA. One fifth of each PCR reaction was then electrophoresed
on a 5% non-denaturing acrylamide gel and autoradiographed.
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